.jpg)
The 4th International Electronic Conference on Cancers
The IECC 2024 is closed! Thanks for your participation!
Welcome to submit your paper to the conference's special issue of Cancers with 20% discount!
Deadline: 31 December 2024.
Submit your proceeding paper (4-8 pages) to Medical Sciences Forum (ISSN: 2673-9992) journal for free!
Deadline: 19 April 2024.
the chairs
Dear Colleagues,
It is a great pleasure to welcome you to the 4th International Electronic Conference on Cancers (IECC 2024), which will be held from 6 to 8 March 2024. The conference is organized by the MDPI open-access journal Cancers (Impact Factor 5.2). It allows scientists from all over the world to present their latest research in Cancers, receive direct feedback, and engage in discussions with the wider scientific community.
In recent years, we have witnessed remarkable breakthroughs in basic cancer research, where discoveries in the genetic and epigenetic tumor make-up and tumor microenvironment have provided valuable insights into the molecular mechanisms underlying cancer initiation, progression, and therapeutic response. This newfound knowledge has laid the groundwork for novel treatment strategies and personalized approaches that hold the potential to revolutionize cancer care. This conference aspires to bring together clinicians and scientists with diverse expertise and perspectives in cancer research to interact, exchange ideas, and form new collaborations that may lead to new advancements in scientific understanding and ultimately impact patient outcomes.
This year’s conference is dedicated to following sessions:
The IECC 2024 will be an online-only proceeding, which allows participation from all over the world with no requirement for travel or related expenditures. An electronic conference provides a platform for rapid and direct exchanges about the latest research findings and novel ideas.
We are committed to equality and inclusion principles. Therefore, we ask authors to ensure that the papers and presentations are highly accessible to the wider and more diverse scientific community. We encourage submissions from scientists at all career stages and backgrounds and aim for an equal gender balance.
The conference will provide 6 awards including Best Oral Presentation Award and Best Poster Award.
We look forward to receiving your contributions to this scientific event and would like to thank you in advance for your active support.
We hope that the community will share this enthusiasm and help make this conference a success.
Sincerely,
Dr. Angeliki Magklara, Dr. Shinji Kawabata, Prof. Dr. Alfredo Conti, Professor Vasso Apostolopoulos
The chair of the 4th International Electronic Conference on Cancers
Welcome to follow us at
Meet the Event Chairs
Important Dates
- Abstract submission deadlineDec 15, 2023
- Abstract acceptance notificationJan 20, 2024
- Registration end dateMar 04, 2024
Meet Our Speakers
Prof. Magdalena Plebanski
School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia;
Distinguished Professor Magdalena Plebanski is an internationally- renowned leader in immunology and bioengineering research, Head of the Translational Immunology and Nanotechnology Theme, and Head of the Cancer, Ageing, and Vaccines Laboratory at School of Health and Biomedical Sciences. She is also Director of RMIT’s Biomedical and Health Innovation Enabling Impact Platform.
Magdalena forged a stellar career in medical and health research. At Oxford University, she showed new ways in which malaria parasites trick the human immune system and pioneered vaccine modifications now widely used around the world. Magdalena globally changed the design of nanoparticle based vaccines, showing smaller sized particles improve immune responses.
Currently, Magdalena interests lie in changing the extremely low survival outcomes from ovarian cancer, by identifying new diagnostic and prognostic biomarkers in the blood. One of her patented biomarkers currently underlies a large-scale Phase II human clinical trial across 15 hospitals around Australia. Magdalena and her team are also testing innovative gold-based immunotherapies in collaboration with RMIT chemists, as well as collaborating with RMIT nanoengineers to develop practical point-of-care diagnostic devices. Magdalena has published more than 200 peer-reviewed full-length papers, including in leading journals such as Lancet, Nature, Science, Immunity, Nature Biotechnology, Nature Medicine and Nature Communications among others.
University Link: https://www.rmit.edu.au/contact/staff-contacts/academic-staff/p/plebanski-magdalena
Linkedin: https://www.linkedin.com/in/magdalenaplebanski/
Google Scholar: https://scholar.google.co.in/citations?user=hMyXlrMAAAAJ&hl=en
Prof. Kulmira Nurgali
Institute for Health and Sport, Victoria University, Melbourne, Australia;
Professor Kulmira Nurgali (PhD 2004, Melbourne University) is a research and teaching academic at the College of Health and Engineering, Institute for Health and Sport, Victoria University, Australia and an Honorary Associate Professor at the Department of Medicine, University of Melbourne, Australia. She is the Head of Enteric Neuropathy Laboratory at the Centre for Health, Research and Education, Sunshine Hospital, Melbourne, Australia and Director of the Stem Cells and Regenerative Medicine Program at the Australian Institute for Musculoskeletal Science. She has an internationally-recognized prominence in the fields of Enteric Neuroscience and Neurogastroenterology. Prof Nurgali’s research is focused on enteric neuropathy associated with Inflammatory Bowel Disease, colorectal cancer, and the side effects of chemotherapy. Being a medical graduate, she focuses on the development of novel treatments and pre-clinical studies that have translational value. Publications and research activity can be found via ORCID ID: 0000-0002-2597-6929.
University Link: https://www.vu.edu.au/contact-us/kulmira-nurgali
Linkedin: https://www.linkedin.com/in/kulmira-nurgali-82291124/
Google Scholar: https://scholar.google.co.in/citations?hl=en&user=oVtmgcgAAAAJ
- Session A. Brain Metastases
- Session B. Cancer Biomarkers
- Session C. Cancer Immunology and Immunotherapy
- Session D. Tumor Microenvironment
- Session E. Molecular Cancer Biology
Sponsors and Partners
Organizer
Media partner
Session B. Cancer Biomarkers
Session D. Tumor Microenvironment
Session E. Molecular Cancer Biology
Session F. Cancer Epidemiology and Prevention
Session G. Cancer Therapy
Session H. Cancer Pathophysiology
Session C. Cancer Immunology and Immunotherapy
Ms. Simon You
Ms. Wynne Yang
Ms. Ariel Zhang
E-Mail: iecc2024@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.